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Lab-On-A-Chip for Oral Cancer Screening and Diagnosis
Abstract
Oral squamous cell carcinoma (OSCC) is a disfiguring and deadly cancer. Despite advances in therapy, many
patients continue to face a poor prognosis. Early detection is an important factor in determining the survival
of patients with OSCC. No accurate, cost-efficient, and reproducible method exists to screen patients for
OSCC. As a result, many patients are diagnosed at advanced stages of the disease. Early detection would
identify patients, facilitating timely treatment and close monitoring. Mass screening requires a rapid oral
cancer diagnostic test that can be used in a clinical setting. Current diagnostic techniques for OSCC require
modern laboratory facilities, sophisticated equipment, and elaborate and lengthy processing by skilled
personnel. The lab-on-chip technology holds the promise of replacing these techniques with miniaturized,
integrated, automated, inexpensive diagnostic devices. This article describes lab-on-chip devices for
biomarker-based identification of oral cancer. Similar methods can be employed for the screening of other
types of cancers.
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Abstract: Oral squamous cell carcinoma (OSCC) is a disfigur-
ing and deadly cancer. Despite advances in therapy, many
patients continue to face a poor prognosis. Early detection is an
important factor in determining the survival of patients with
OSCC. No accurate, cost-efficient, and reproducible method
exists to screen patients for OSCC. As a result, many patients
are diagnosed at advanced stages of the disease. Early detec-
tion would identify patients, facilitating timely treatment and
close monitoring. Mass screening requires a rapid oral cancer
diagnostic test that can be used in a clinical setting. Current
diagnostic techniques for OSCC require modern laboratory
facilities, sophisticated equipment, and elaborate and lengthy
processing by skilled personnel. The lab-on-chip technology
holds the promise of replacing these techniques with miniatur-
ized, integrated, automated, inexpensive diagnostic devices.
This article describes lab-on-chip devices for biomarker-based
identification of oral cancer. Similar methods can be employed
for the screening of other types of cancers. VC 2007 Wiley Peri-
odicals, Inc. Head Neck 00: 000–000, 2007
Keywords: oral cancer; lab-on-a-chip; microfluidics; bio-
markers; screening
Head and neck cancers are the sixth most com-
mon cancer worldwide and are associated with low
survival and high morbidity.1 Cancers of the oral
cavity account for 40% of head and neck cancers
and include squamous cell carcinomas of the
tongue, floor of the mouth, buccal mucosa, lips,
hard and soft palate, and gums.2,3 Despite thera-
peutic and diagnostic advances, the 5-year sur-
vival rate for oral squamous cell carcinoma
(OSCC) remains at about 50%.2–4 In addition,
aggressive treatment of OSCC cancer is controver-
sial since it can lead to severe disfigurement and
morbidity.5 As a result, many patients with OSCC
cancers are either over- or under-treated with sig-
nificant personal and socio-economic impact.
One of the major factors accounting for the
poor outcome of patients with OSCC is that a
great proportion of oral cancers are diagnosed at
advanced stages and, therefore, treated late.
Early detection of pre-malignant or oral cancer
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lesions will greatly reduce morbidity associated
with late disease treatment and improve overall
patient survival. For example, early detection
could lead to frequent patient monitoring, dietary
changes, counseling for cessation of smoking and
drinking, preventative drug administration, and
lesion removal. Indeed, early diagnosis and treat-
ment of OSCC lead to a mean survival rate of over
80% and a good life quality after treatment.6
Thus, screening methods are needed to detect
OSCC cancers.
For most practitioners, visual screening of
patients for precancerous or cancerous lesions is
the most common screening method. Recent stud-
ies in India have reported that oral visual screen-
ing can reduce mortality in high risks individuals
(tobacco and alcohol users7–9). However, visual
screening is limited in that it only identifies
whether a lesion is present. Visual screening can-
not, for example, determine the progression of a
stage I or stage II tumor to stages III/IV or distin-
guish which leukoplakia or dyplastic lesions will
progress to carcinoma. Therefore, a screening sys-
tem is needed that will identify which pre-cancer
lesions will progress to cancer.
Currently, clinical examination and histopath-
ological studies are the standard diagnostic
method used to ascertain whether biopsied mate-
rial is a precancerous or cancerous lesion.10,11
The reliance on biopsies has several drawbacks:
(1) biopsies are invasive procedures and, depending
on the site, often involve surgical techniques and
anesthesia; (2) small lesions may not provide suffi-
cient material for accurate diagnosis; (3) biopsies
from sites within a large lesion may not reflect the
entire histopathological aspects of the lesion; (4)
biopsies are inherently subjective in nature; and (5)
sensitivity and specificity of biopsies are limited,
increasing the potential for flawed diagnosis and
an inappropriate therapeutic approach. Thus,
additional methodologies are necessary to detect
pre-malignant andmalignant oral cancer lesions.
Non-invasive detection of pre-malignant and
malignant oral cancer cells requires easy access
to the site where these cancers typically arise and
a readily available source of cancer cells. The oral
cavity meets both of these criteria. Saliva from
the oral cavity, because of its cellular composi-
tion, accessibility, and inexpensive and non-inva-
sive methods of collection, is ideal as a diagnostic
medium for oral cancer detection. Flow cytometry
analysis of human saliva has demonstrated that
saliva is composed of live and dead erythro-
cytes, leukocytes, and epithelial cells.12 However,
distinguishing normal, precancerous, and cancer-
ous cells from the other cellular populations in
saliva requires not only capture and enrichment
of the precancerous and cancerous cells, but also
cancer-specific biomarkers.
In this review, we will discuss combining bio-
marker detection and microfluidic lab-on-a-chip
technology to develop a device for early screening
of oral cancer. This microfluidic chip will accept
saliva samples, will be operated by minimally
trained personnel, and will provide a diagnostic
answer in an automated and timely fashion. The
detection of oral pre-cancer (dysplastic) and can-
cer cells within the chip will take advantage of
membrane-associated cell proteins that are singu-
larly expressed on the cell membranes of dysplastic
and cancer cells and of the unique gene transcrip-
tion profiles of cancer cells. As such, this system
will provide a means for automated, rapid detec-
tion and molecular analysis of cancers in a minia-
turized format suitable for use in the clinic and/or
the operating room.
MOLECULAR TARGETS FOR THE ISOLATION
OF ORAL CANCER CELLS
Analysis of exfoliated cells in saliva is the most
direct method for screening oral pre-cancer and
cancer lesions. Several approaches have been
devised to detect oral precancer and cancer cells
in saliva. Cytology is the most straightforward
way and involves pathological evaluation of the
exfoliated smear. Several variations or improve-
ments to exfoliated cell cytology have been tested
and include staining for the presence of micronu-
clei, detection of microsatellite instability (MSI)
by polymerase chain reaction (PCR), fluorescence
in situ hybridization (FISH) analysis, promoter
hypermethylation, and mitochondrial DNA con-
tent.13–18 While promising, these methods all
involve analyzing the entire cellular population
contained within salvia. Such an approach may
have low sensitivity for tumor cell detection,
especially pre-cancer cells.19 To improve the sen-
sitivity of pre-cancer and cancer detection, a
method that enriches the pre-cancer and cancer
cells from the cellular population of saliva would
be preferable.
Expression of cancer-specific membrane pro-
teins that could be used to discriminate cancer
cells from normal cells and facilitate identifica-
tion, capture, and enrichment of cancer cells
would be ideal. For example, antibodies against
cancer-specific membrane proteins conjugated
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with labels such as fluorescent antibodies and
quantum dots or beads (magnetic, metallic) can
preferentially tag the cancerous cells in a sample.
However, unique proteins expressed by the cancer
cells must first be identified. Several recent
reports have identified oral pre-cancer (dys-
plastic) and cancer cells express 2 membrane gly-
coproteins, which are either absent or minimally
expressed in the membranes of normal cells.
Interestingly, these same glycoproteins are being
targeted for immunotherapeutic approaches for
cancer treatment and therefore are excellent can-
didates for cancer diagnostics as well (Personal
communication, Dr. Nick Glover, President,
Viventia Biotech Inc.).20
Hsp-47, also known as colligin, is normally an
endoplasmic reticulum (ER) resident protein with
collagen binding properties. However, in several
disease states including oral cancer development
and progression, Hsp-47 modulates collagen pro-
duction by locating to the cell surface mem-
brane.20 In oral cancers Hsp-47 is characterized
as being present only on cancer cells where it is
typically over expressed.20,21 As such, Hsp-47 has
been designated as a specific marker for oral can-
cer detection and as a potential biomarker for
therapeutic targeting of oral cancers.21 Like Hsp-
47, EpCAM is also a cell surface protein found on
cancer cells of the oral cavity.
EpCAM is a 40-kDa epithelial transmembrane
glycoprotein that is strongly expressed in several
epithelial cancers including colon, prostrate, head
and neck, esophagus, lung, and breast.22 EpCAM
is not expressed by hepatocytes, thymic cortical
epithelial cells, gastric parietal cells, myoepithelial
cells, and many other non-epithelial cells.23
EpCAM-negative squamous epithelial cells can
express EpCAM upon transformation where the
amount of EpCAM and the number of EpCAM
expressing cells increases with the grade of dyspla-
sia.24 In more recent studies, EpCAM was found in
>89% of all head and neck OSCC tumor speci-
mens analyzed.25 Furthermore, EpCAM has been
detected in the majority, and expressed signifi-
cantly higher, in primary squamous cell carcinoma
of the tongue than in normal oral mucosa.26 It was
concluded from this study that EpCAM could be a
molecular target for oral cancer. In agreement
with this study, Chaubal et al27 have demonstrated
that EpCAM can be used as a tumor marker for
the diagnosis of single tumor cells in patients with
head and neck cancers. Thus, EpCAM appears to
be an ideal cell surface protein for enriching oral
pre-cancer and cancer cells from the saliva.
Additional studies, using magnetic beads
coated with EpCAM antibodies, have shown that
tumor cells can be efficiently isolated from saliva-
like samples containing mononuclear cells. In
initial work, saliva was replicated by mixing lym-
phocytes, obtained from healthy volunteers with
cells from 3 human oral cancer cell lines at vary-
ing cell numbers in binding buffer. Magnetic
beads functionalized with EpCAM antibodies
were added and the number of tumor cells recov-
ered was determined. The recovery yield was on
average >80% in all cell lines and independent of
the number of cancer cells.19 In agreement with
this initial study, we have determined that using
antibodies specific for EpCAM we can isolate can-
cer cells in saliva obtained from patients with var-
ious OSCC TMN staged tumors and dysplastic
lesions but not from healthy patients, with a false
positive rate <0.05% (Figure F11). This is accom-
plished by removing interfering cells from saliva
such as mononuclear cells and capturing the tu-
mor cells with magnetic beads coated with anti-
bodies specific to this membrane glycoprotein.
Thus, the capture, enrichment, and counting of
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FIGURE 1. Isolation of tumor cells from OSCC patients’ saliva.
Using negative selection with magnetic beads bound to anti-
lymphocyte antibodies, followed by positive selection with
magnetic beads functionalized with antibodies to specific cell
surface glycoproteins, we isolated the dysplastic and oral can-
cer cells. The total number of dysplastic or cancer cells isolated
is depicted as a function of the stage (TNM) of the disease.
Since the tumor cell yield depends on the size of tumor above
or exposed to the mucosal surface (tumor cells below the mu-
cosal surface do not slough off), there was only a weak correla-
tion between the collected amount of cancer cells and tumor
stage or size. Essentially, no cells were isolated from healthy
patient saliva.
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the cancer cells isolated from a clinical sample
using EpCAM can serve as an initial screen for
cancer and, in itself, is a useful medical test. How-
ever, to gain additional information about the type
and stage of the cancer, it is desirable to obtain the
gene expression profile of the isolated cells.
GENE EXPRESSION PROFILING
Gene expression profiles have shown dramatic
correlations with tumor development and pro-
gression, lymph node invasiveness, recurrent dis-
ease, and patient outcome when applied to biopsy
samples.28–31 Typically, genetic changes in cancer
cells lead to altered gene expression patterns that
can be identified long before the cancer phenotype
has manifested (FigureF2 2). When compared with
normal mucosa, the changes that occur in the
cancer cell can be used as biomarkers. Several
candidate genes associated with OSCC tumor
progression such as p53, cyclin D1, and epidermal
growth factor receptor (EGFR) gene have been
identified.32 However, to date, no single gene has
shown sufficient diagnostic utility in OSCC.
Thus, as in many other cancers, clinical diagnosis
will require considering the combined influence
of many genes.
Expression patterns of sets of genes have
shown dramatic correlations with tumor behavior
and patient outcome. Microarray analysis of sev-
eral tumor types has demonstrated that global
expression profiling can distinguish tumor cells
from normal cells, as well as identify the class and
subtype of cancer far superior to current histo-
pathological diagnostic methods.33–35 Finally, the
advent of high density microarrays, advances in
bioinformatics, and the discovery of molecular sig-
natures for dysplasia and cancer have opened the
door for inclusion and adaptation of these gene
signatures intomicrofluidic lab-on-a-chip devices.
Recent independent studies carried out by vari-
ous research groups including our laboratory
indicate that OSCC cells have a unique gene tran-
scription profile, which differs from that of normal
cells.30,33,34 These studies found a set of genes that
are significantly down or upregulated in OSCC
tumors.30,33–35 To identify an OSCC tumor predic-
tor, microarray data obtained from paired OSCC
tumors and normal tissues was analyzed by the
class prediction algorithm Support Vector
Machines (SVM,36 AQ2). SVM and the Goloub method
were used to identify 25 geneswith the highest pre-
dictive strength.28,30 Cross-validation of patient
tumor and normal data demonstrate that this
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FIGURE 2. Illustration of differences between normal and cancer cells. Potential cancer biomarkers exemplified by genetic changes in
the chromosomal DNA are illustrated in the cancer cell. Typical changes in the host DNA such as point mutations, deletions, transloca-
tions, amplifications, and methylations alter mRNA transcripts from these affected genes. These affected mRNA transcripts could be
lost, mutated, or increased. As a result of the mRNA changes, cellular protein products from these affected genes are similarly altered.
The altered proteins in the cancer cell are expressed intracellularly, on the cell surface, or secreted into the extracellular space at
higher or lower levels compared to normal cells. Exploitation of specific changes that occur in the cancer cell’s RNA or protein pro-
vides convenient targets to enrich the cancer cells from normal cells and other cell types. [Color figure can be viewed in the online
issue, which is available at www.interscience.wiley.com.]
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25-gene set predictor could classify tumor and nor-
mal samples with 96% accuracy. So far, microarray
data from a total of 44 OSCC and normal speci-
mens obtained from the University of Pennsylva-
nia, the University of Pittsburgh, and data sets
fromGeoData Set, NCBI have been tested. The 25-
gene predictor correctly classified all samples pro-
ducing average accuracy rates of 87% to 100%.
Finally, using existing Affymetrix U133A chip
derived data sets (NCBI Geo DataSets) from 20
other human tumors including breast, renal clear
cell tumor, acute myeloid leukemia, lymphoblastic
leukemia, and Barrett’s associated adenocarcino-
mas resulted in accuracies of <25%. In short, by
microarray analysis, a significant tissue-specific
transcription profile from 25 genes that can accu-
rately predict OSCC tumor and distinguish
between OSCC tumor and normal tissue has been
identified. This 25 gene predictor for oral cancer
would be a good way to detect the presence of oral
cancer in saliva using a lab-on-a-chip device. How-
ever, whether these same predictors can be used
for detection of saliva derived pre-cancer and can-
cer cells has yet to be tested.
For human cancer, nucleic acid-based meth-
ods provide the most accurate means of detecting
biomarkers. This is primarily due to the tremen-
dous sensitivity and specificity of PCR and other
nucleic acid hybridization-based amplification
and assay techniques. Although in some cases,
free-floating RNA can be detected in clinical sam-
ples, the utility of cell-free RNA as a diagnostic is
controversial.37,38 In general, the nucleic acids of
interest are sequestered inside host cells. The
processing and identification of these nucleic
acids requires capture and isolation of target can-
cer cells; then lysis; nucleic acid isolation by, for
example, solid phase extraction or hybridization;
PCR; and amplicon labeling and detection.39–46
Early work has indicated that mRNA from exfoli-
ated saliva cells is somewhat degraded. This was
expected since the cells assayed in this study
were terminally differentiated oral epithelial
cells.47 Since pre-cancer and cancer cells present
in saliva are more likely to be undifferentiated,
they should still be actively manufacturing
mRNA. In agreement with this notion, recent
work by Spivack et al48 has demonstrated that
RNA can be isolated, amplified using reverse
transcription-PCR and used for gene expression
analysis from exfoliated cancer cells from the oral
cavity. However, to date, no gene expression
profiling using exfoliated cells obtained from sa-
liva has been reported. Besides RNA, DNA from
exfoliated cells has also been examined as a
means to screen for oral cancers.
Regions of DNA instability, frequently found
in many cancers, have been tested as a screen for
oral cancer using saliva samples.16,49 For exam-
ple, using saliva obtained from tumor patients
Okami et al16 detectedMSI in 80% of the samples.
These results suggest that MSI has the potential
to be used as a molecular screening for oral
cancers. More recent work using a similar MSI
approach has shown that loss of heterozygosity or
MSI of at least 1 marker can be detected in 79% of
the oral cancer saliva samples with no microstael-
lite alterations detected in normal saliva.15 Thus,
MSI appears to be a sensitive means of detecting
cancer cells in the exfoliated cell population of
saliva.Whether,MSImethods can be used to detect
pre-cancer lesions has not been reported. Besides
MSI, several other methods using DNA have been
examined as potential screens for oral cancers.
DNAFISH has also been tested as an approach
for screening oral cancers.14 Recent work has
shown that interphase FISH can detect chromo-
some imbalances associated with malignancy.14
In addition to FISH, aberrant promoter hyper-
methylation patterns of cancer-related genes in
saliva of head and cancer patients has been shown
to be potentially useful in detecting and monitor-
ing disease recurrence.18 For example, Rosas
et al50 identified abnormal promoter hypermethy-
lation in saliva samples from 65% of the patients
with oral cancers. Finally, PCR was used to detect
changes in mitochondrial DNA from exfoliated
pre-cancer cells of the oral cavity. This worked
demonstrated that mitochondrial DNA increases
with histopathlogical grade. Thus, while PCR
seems the most sensitive method for detection of
pre-cancer and cancer cells in saliva, several DNA
methods have potential applications for oral pre-
cancer and cancer screening. However, more work
is required to determine which of these DNA
methods could be used in a lab-on-a-chip device.
MICROFLUIDICS AND LAB-ON-A-CHIP
Broadly, microfluidics technology—also referred to
as lab-on-a-chip or micro-total-analysis systems
(lTAS)—is the adaptation, miniaturization, inte-
gration, and automation of analytical laboratory
procedures into a single device or \chip."Microflui-
dics is often regarded as the chemistry or biotech-
nology equivalent of the silicon integrated circuit
chip that has revolutionized electronics, compu-
ters, and communications. Currently, microfluidic
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systems are under development for disease diag-
nostics, controlled drug delivery, drug discovery,
detection of bioterrorism agents, and air and water
qualitymonitoring.39,40,43–46,51–55AQ3
In its most comprehensive medical use, the
microfluidic diagnostic system would accept and
process a small biopsy or a small sample of blood,
saliva, lung aspirations, urine, or intraductal
breast fluid; and then it would provide an easy-to-
interpret readout indicating the presence and
quantity of specific molecules, such as pathogen
antigens, nucleic acids, antibodies, metabolites,
toxins, drugs, and cancer markers, in the sample.
The potential benefits of microfluidics derive from
the use of small sample volumes, automated oper-
ation, short processing times, reduced reagent
consumption, reproducibility and consistency,
reduced exposure to hazardous materials or
infectious agents, minimal risk of sample contam-
ination, convenient disposal, operability by mini-
mally-trained personnel, and low cost. Finally,
microfluidics will bring the power of sophisticated
analytical techniques to rural areas and develop-
ing countries where conventional analytical labo-
ratories are lacking.
Some of the more fundamental engineering
challenges and design issues for microfluidic sys-
tems are related to the propulsion, stirring, and
flow control of the sample and reagents within the
small (sub-millimeter) conduits of the chip. For
example, within the microfluidic device, the stir-
ring and mixing of reagents under the laminar
flow conditions characteristic of microfluidics is a
challenging problem. Microfluidic devices have
incorporated various ingenious concepts, ranging
from the miniaturization of macroscopic pumps
and valves to novel propulsion techniques that
utilize electro-kinetic, magnetic, surface (capil-
lary), and osmotic forces.56–59 Likewise, various
microfluidic PCR thermal cyclers have been
demonstrated, ranging from batch-mode, temper-
ature-regulated chambers to continuous-flow
reactors in which the PCR cocktail is pumped
through a series of heated zones maintained at
different fixed temperatures.60,61 Another issue is
the choice of detection modalities to be interfaced
with the chip to identify the target molecules. Pos-
sibilities include laser-induced fluorescence,
chemi- or bio-luminescence, electrochemical sens-
ing, plasmon surface resonance, and piezo-electric
transducers.
Simple \microfluidic" diagnostic devices such
as lateral-flow and consecutive flow assays for
home-pregnancy testing, drug abuse testing,
prostate-specific antigen (PSA) detection, saliva-
based HIV testing, as well as tests for bacterial
contamination of food andwater are already avail-
able on the market today.62 The lateral flow strip
comprises a porous nitrocellulose membrane or
capillary network, striped with one or more cap-
ture zones of immobilized antibodies that specifi-
cally bind target molecules. Serum, urine, or sa-
liva samples blotted onto the strip flow through
the porous membrane by capillary action, and
molecules contained in the sample bind to the cap-
ture zone. These molecules are tagged with sec-
ondary antibodies conjugated with labels such as
carbon or gold particles, fluorescent/phosphors, or
enzymes that convert a substrate compound to a
luminescent reporter or electrochemical agent.
These labels render the captured molecules visi-
ble to the naked eye or facilitate detection with an
optical or electrochemical detector.
Although it is feasible to construct a com-
pletely self-contained microfluidic system that
includes micropumps, microvalves, and detection
devices fabricated directly into the cassette or
chip, this approach is deemed uneconomical for
medical diagnostics. Instead, an inexpensive, sin-
gle-use, disposable credit card-sized microfluidic
cassette is designed to mate with a portable
instrument that provides fluidic power, flow con-
trol, regulated heating and cooling, signal detec-
tion, and data processing. Suitable microfluidic
components are selected and integrated into the
cassette according to: (1) the disease or ailment
and the specific diagnostic information sought; (2)
the biological basis of the clinical test (eg, immu-
noassay, cell sorting and detection, gene detection,
and transcription or protein expression profiling);
and (3) the sample type (eg, tissue, whole blood,
serum, saliva, urine). By selection of appropriate
PCR primers or antibodies and modifications of
basic operating protocols, it is feasible to reconfig-
ure the microfluidic system for diagnostics of
many types of cancers based on protein or RNA
detection.63,64
A fully-integrated lab-on-a-chip for cancer
diagnostics will require integration of components
for cell sorting (in order to deplete the sample of
non-cancer cells and/or enrich the sample with
the target cancer cells), cell lysis, nucleic acid iso-
lation, multiplex RT-PCR or biobarcode amplifica-
tion, and multiplex detection of labeled PCR prod-
ucts or sorted biobarcodes. For the most part, \on
chip" processes to perform these assays have been
described. For example, Anderson et al41 have
designed a credit card size chip that is capable of
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extracting and concentrating nucleic acids from
milliliter aqueous samples and performing micro-
liter chemical amplification, serial enzymatic
reactions, metering, mixing, and nucleic acid
hybridization. Similarly, a microfluidic system
that can perform cell lysis and DNA amplification
was developed by Lee et al.46 Furthermore, Liu
et al have constructed a microfluidic cartridge
that can automate the fluidic handling steps
required to carry out a microarray gene expres-
sion study of human leukemia.43 The fully inte-
grated microfluidic device consists of microfluidic
pumps/mixers, fluid channels, reagent chambers,
and a DNA microarray silicon chip. Microarray
hybridization and subsequent fluidic handling
and reactions (including a number of washing and
labeling steps) can be performed in this fully auto-
mated and miniature device before fluorescent
image scanning of the microarray chip. In addi-
tion, Marcus et al have utilize microfluidics to iso-
late picogram and subpicogrammRNA templates,
as well as to synthesize cDNA from individual
cells while Chang et al have described a microflui-
dic chip that can perform PCR.65,66 Finally, Tsai
have developed a micro-RT-PCR (microRT-PCR)
chip that is designed to quantitatively detect tu-
mor viruses.67 The next steps will be to integrate
all these processes onto a single chip. To develop a
cancer diagnostic lab-on-a-chip, for example based
on transcriptional profiling of a sub-population of
cancer cells in a clinical specimen, will more than
likely require a time frame of 1 to 2 years to dem-
onstrate feasibility, and another 2 to 5 years for
the development of prototypes suitable for clinical
trials.
LAB-ON-A-CHIP BASED ORAL CANCER DETECTION
Screening for and diagnosis of head and neck can-
cers using oral fluid samples provides an illustra-
tive case study for developing a microfluidics
cancer detection and analysis system. A device
based on an inexpensive, disposable microfluidic
cassette, such as the one shown in FigureF3 3, with
pre-loaded, freeze-dried reagents, and used in
conjunction with a handheld instrument would
promote early screening and diagnostics during
dental visits or routine medical exams. The
patient would provide 1 mL of saliva, which is
taken up by a sponge-tipped disposable collector.
The collector is inserted into the cassette to inject
the collected oral fluid through a sample inlet
port. Within the microfluidic lab-on-a-chip device,
antibodies conjugated to magnetic beads would
assist in removal of all lymphocytic cells. Next,
the target pre-cancer and cancer cells would be
captured and enriched from the sample using
magnetic beads functionalized with antibodies to
the specific dysplastic and cancer expressed cell
surface glycolproteins (for example EpCAM). The
cancer cells would be isolated and detected. The
detection of cancer cells provides an initial indica-
tion of the presence of disease.
Subsequently, the isolated cancer cells would
be lysed by thermal or osmotic shock, and their
nucleic acid content isolated and purified using
solid-phase extraction (eg, chaotrope-induced,
selective binding of nucleic acids to a silica solid
phase followed by elution of pure nucleic acids).
Alternatively, the RNA released from the lysed
cells could be hybridized to magnetic beads func-
tionalized with poly-T to capture any mRNA or
functionalized with complementary oligonucleo-
tides to capture gene specific transcripts of inter-
est. An external magnetic field will be used to
manipulate the magnetic beads suspended inside
the fluidic circuits of themicrofluidic chip.
The isolated specific mRNAs are then be
reverse transcribed and, when needed, amplified
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FIGURE 3. Example of a microfluidic lab-on-a-chip. The saliva
sample is introduced into the sample port. The saliva sample is
lysed with enzymes, detergent, and chaotropic salts in a two-
step, two-chamber lysis process. The nucleic acids are isolated
from the lysate by solid-phase extraction using a porous silica
membrane as a nucleic acid binding phase. Purified nucleic
acids eluted from the silica membrane are amplified by PCR
using specific primers. The PCR amplicons are labeled with up-
converting phosphor particles and conjugated to antigens, then
run on a blotted nitrocellulose strip, where they are captured by
immobilized antibodies and detected by a laser scanner. Similar
pathogen detection chips, now widely developed by many
groups throughout the world, can be adapted for cancer screen-
ing and serve as a basis for more sophisticated lab-on-a-chip
cancer diagnostics systems. The chip pictured above is made
of polycarbonate plastic and measures 10 cm in length and
3 cm in width. [Color figure can be viewed in the online issue,
which is available at www.interscience.wiley.com.]
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with linear RNA amplification. The expression
levels are detected with multiplex Real Time-
PCR or with non-enzymatic techniques such as
bio-barcodes. FigureF4 4 depicts a schematic of a
bio-barcode, bead-based process for isolation of
total mRNA, followed by multiplex amplification
and detection of a panel of mRNAs. Multiple-
xed, non-enzymatic amplification of DNA with
bio-barcodes is a less demanding assay than mul-
tiplexed PCR.63,64
Multiplexed DNA (or protein) detection with
bio-barcodes will provide a gene transcription pro-
file that is highly predictive of oral cancer. Ampli-
fication products can be labeled and detected by
fluorescence, phosphorescence, chemi- or bio-
luminescence, or electrochemical sensing. For
J_ID: HED Customer A_ID: 06-0558.R1 Cadmus Art: HED20680 Date: 11-APRIL-07 Stage: I Page: 8
ID: srinivasanv Date: 11/4/07 Time: 15:43 Path: J:/Production/HED#/Vol00000/070082/3B2/C2HED#070082
FIGURE 4. Cancer diagnostics format based on magnetic bead cell sorting and multiplex detection of a panel of mRNAs using bio-
barcodes. The cell-laden sample containing normal cells, cancer cells, and lymphocytes is introduced into the microfluidic cassette [1].
The cell suspension is mixed [2] and incubated [3] with magnetic beads functionalized with anti-CD45 antibody that specifically binds
to lymphocytes. An external magnetic field isolates the lymphocytes-magnetic bead complexes from the solution. [4] The supernatant,
depleted of lymphocytes, [5] is mixed and incubated [6] with magnetic beads functionalized with antibodies to membrane glycoproteins
specific to cancer cells (such as EpCAM and HSP47) and with quantum dots conjugated with the same antibodies as the magnetic
beads or different antibodies specific to membrane proteins of cancer cells. The cancer cell-bead-quantum dot complexes are isolated
from the solution with the aid of an external magnetic field. [8] The compartment is washed to remove any unbound quantum dots. An
estimate of the number of cancer cells is obtained with a CCD camera. The immobilized cancer cells are lysed, [9] and then mixed
and incubated with magnetic beads functionalized with oligonucleotides complementary to a pre-selected set of mRNAs and to house-
keeping genes. [10] The magnetic beads with captured mRNAs are isolated by application of an external magnetic field and thoroughly
washed. [11] The captured mRNAs are hybridized with nanoparticles with oligonucleotides complementary to the specific cancer cell
mRNA and the barcode DNAs [12] to form barcode-magnetic bead-selected mRNA sandwiches. [13] The magnetic beads are immobi-
lized and the solution is washed. [14] The barcode DNAs are removed from the beads [15] and detected by fluorescence using a
fiber optic array. [16] The measured profile is compared with archived gene transcription profiles to determine the cancer type and
stage. The detection method described here combines the bio-barcode format of Mirkin and coworkers64 and the fiber optic bead
array of Walt and coworkers.68 Figure drawn by M. Mauk, 2006. [Color figure can be viewed in the online issue, which is available at
www.interscience.wiley.com.]
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example, the amplified gene transcripts can be
detected and quantified by a hybridization-based
optical biosensor such as miniaturized fiber optic
bundle arrays.68 These fiber optic sensors serve as
a low-cost alternative to gene chip microarrays
and can be efficiently interfaced with and optically
coupled to amicrofluidic chip.
The transcription profile of the isolated sam-
ple cancer cells will be compared with cancer sig-
nature profiles archived in a database using
established statistical rules to identify the type of
cancer and to discriminate between cancer and
normal samples. This method will provide near-
real time diagnostic reports in the form of speci-
fic gene transcription signature data in 10 to
60minutes.
It is also important to note that the microflui-
dic devices described here could be easily adapted
and tailored for the diagnosis and analysis other
cancers andmonitoring treatment.
FUTURE APPLICATIONS AND DIRECTIONS
In the long term, we envision a detection system
that consists of an inexpensive, single-use, dispos-
able cassette that operates in conjunction with a
moderately priced, portable analyzer. Various
types of cassettes will accommodate different tests
to be identified through a bar code on the cassette.
The bar code will direct the analyzer to carry out
an appropriate sequence of operations. By keep-
ing the analyzer generic, it would be possible to
reduce its cost; approximately $50 for each test
cassette and a one time cost of $5 to $2000 for the
analyzer.
In addition to applications for cancer detection
including point-of-care screening, the lab-on-a-
chip will provide a means for cancer typing and
staging, monitoring of disease progression and re-
currence, assessing the effectiveness of therapies,
and detecting drug resistance. In the operating
room, the chip will aid the surgeon in defining the
clear boundaries after tumor extraction and assist
in the assessing whether the primary tumor has
spread to the lymph nodes. Finally, with the incor-
poration of the appropriate assays and detection
systems, the lab-on-a-chip could be used to detect
gene mutations, hetero- or homozygosity, loss of
function, chromosomal translocations, cancer-
related methylation, and other alterations that
have been shown to play a role in oral cancer de-
velopment and progression.
Research, development, and optimization of
microfluidic diagnostics technology continues.
Workable, albeit perhaps not optimal, components
for the lab-on-a-chip operations necessary to pro-
cess clinical samples for oral cancer diagnosis,
such as magnetic-bead based cell sorting, protein
and nucleic acid isolation with magnetic beads
and/or solid-phase binding media, incubation and
temperature cycling, reverse transcription, quan-
titative PCR, and enzymatic and non-enzymatic
signal amplification and detection, have been
adequately demonstrated. The remaining major
challenge is to seamlessly integrate the various
components into a single microfluidic cassette
amenable to automated operation and optimize
multiplexing capability for 5 to 30 protein or
nucleic acid targets.
Microfluidics appears poised to make a signifi-
cant impact on the technology and practice of oral
cancer screening and diagnostics and on heath
care in general. In fact, a few simple microfluidic
diagnostic devices are now available, or are reach-
ing demonstration stages in academic and indus-
trial laboratories. Unfortunately, there are still
many questions regarding the identification of
various expression profiles, establishing their pre-
dictive power, and developing procedures to col-
lect, process, and analyze specific cancer samples
and derive clinically useful information utilizing
these cancer markers. Synergism from coordi-
nated development of practical lab-on-a-chip
systems in parallel and close collaboration with
supporting and exploratory biomedical and clini-
cal research would foster progress in both micro-
fluidics technology and cancer diagnostics and
therapeutics. The advent of low-cost, mass-pro-
duced, and convenient-to-use microfluidic cancer
diagnostic systems would accelerate cancer
marker research and facilitate broad-based clini-
cal trials with large numbers of human subjects
which ultimately would lead to decreases in
patient morbidity andmortality.
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